Clevidipine
From Wikipedia, the free encyclopedia
 |
|
|
Clevidipine
|
|
| Systematic (IUPAC) name | |
| O3-(butanoyloxymethyl) O5-methyl (4R)- 4-(2,3-dichlorophenyl)-2,6-dimethyl- 1,4-dihydropyridine-3,5-dicarboxylate | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C21H23Cl2NO6 |
| Mol. mass | 456.316 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Intravenous |
Clevidipine (INN; planned trade name Cleviprex) is an ultra short-acting[1] calcium channel blocker which is currently under regulatory review by the United States Food and Drug Administration for the treatment of acute severe hypertension.
[edit] References
- ^ Gradman AH, Vivas Y. New therapeutic perspectives with clevidipine: an ultra-short-acting intravenous Ca2+ channel blocker. Expert Opin Investig Drugs 2007;9:1449-57. PMID 17714030.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
